Navigation Links
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Date:4/20/2009

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response -

- Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall -

TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel showed that 11 of 17 evaluable patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) achieved an objective tumor response according to RECIST criteria, after completing the maximum six treatment cycles. The company also reported that patient dosing is underway in the expansion stage of the trial, which will enroll an additional 28 patients for a total of 49 patients overall.

"We are very pleased to see these additional objective tumor responses in this difficult-to-treat cancer following the full regimen of six treatment cycles of bavituximab and chemotherapy," said Steven W. King, president and CEO of Peregrine. "These updated results build on the impressive data we reported after only four treatment cycles, which had already exceeded the pre-defined number of objective tumor responses needed to expand the trial to the larger cohort."

Mr. King added, "The tumor response data to date from this trial compares favorably to published studies with current standard-of-care lung cancer treatments, and we are looking forward to seeing results from the entire study. With dosing now underway in the expanded patient cohort, we expect to resume the brisk pace of enrollment achieved in the first cohort, with the goal of completing patient
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. ... inoperable solid tumor cancers, announced today that CEO Linda ... Phacilitate Immunotherapy Forum in Washington D.C. ... on January 26 at 10:30 a.m. EST at the Grand ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... Local Treatment of Oral Candidiasis in Immunosuppressed Patients in China ... 5 RHEI Pharmaceuticals, Inc. today announced that the final ... dose miconazole in a patented mucoadhesive system, has been initiated ... conducted for submission of the New Drug Application (NDA) to ...
... Orexigen(R) Therapeutics, Inc.,(Nasdaq: OREX ) today ... on its late-stage obesity programs and realign its,management team. ... aspects of these changes are as follows: , ... proof-of-concept Phase 2 trials for OREX-003,(zonisamide and olanzapine to ...
Cached Medicine Technology:RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... , WICHITA, Kan., Aug. 10 Operation Rescue ... aimed at stopping abortionist LeRoy Carhart from opening an international late-term ... considered an urgent priority in a larger c a ... in any state. , , In order for Carhart ...
... Chairman ... , ... (PRWEB) August 10, 2009 -- This year,s National Association of Chain Drug Stores ... focused extensively on the healthcare reform debate. During the 52nd annual Conference, experts ...
... , , NEW YORK, Aug. 10 ... leading global information and media company and the CLIO Awards, one of the ... the online entry system, currently open at www.CLIOHealthcare.com for first-ever CLIO ... has been extended. For all work appearing between January 1, 2008 and June ...
... , PITTSBURGH, Aug. 10 ... of diagnostic imaging professional services and Vital Images (Nasdaq: ... analysis software, have partnered to bring Vital Images, advanced visualization ... full suite of software exclusively with its customer base of ...
... idiopathic chronic cholestatic inflammatory liver disease characterized by diffuse ... in bile duct obliteration, biliary cirrhosis, and eventually hepatic ... time of presentation of PSC is mild to severe ... the mechanisms responsible for the abdominal pain in PSC ...
... or ,borrowed, drugs, study found , MONDAY, Aug. 10 (HealthDay ... drugs such as antibiotics and allergy medications with friends, a ... new study. , For example, a teen who,s taking the ... defects -- may give some to a friend who is ...
Cached Medicine News:Health News:Urgent Petition Launched to Block Plans for New International Late-Term Abortion Clinic 2Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 2Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 3Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 4Health News:Nielsen Announces Entry Deadline Extension for the First-Ever CLIO Healthcare Awards 2Health News:Foundation Radiology Group and Vital Images' Partnership Brings Advanced Visualization to Small Medical Communities Nationwide 2Health News:Gallbladder emptying in primary sclerosing cholangitis patients 2Health News:Sharing Prescription Meds Common Among U.S. Teens 2
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... purified non-ionic fraction of agar. Forms gel ... concentrations. Can be mounted on microscope slides ... elastic and durable and show little or ... or lipoprotein dyes. Contaminants: ash: ...
Medicine Products: